ARGX
argenx NV ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$56.56B
P/E Ratio
40.28
EPS
$22.47
Beta
-0.03
52W High
$934.62
52W Low
$510.06
50-Day MA
$809.91
200-Day MA
$806.85
Dividend Yield
—
Profit Margin
31.40%
Forward P/E
34.01
PEG Ratio
1.51
About argenx NV ADR
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Fundamentals
| Revenue (TTM) | $4.74B |
| Gross Profit (TTM) | $2.76B |
| EBITDA | $1.32B |
| Operating Margin | 30.00% |
| Return on Equity | 20.20% |
| Return on Assets | 8.86% |
| Revenue/Share (TTM) | $3.08 |
| Book Value | $4.73 |
| Price-to-Book | 7.63 |
| Price-to-Sales (TTM) | 11.93 |
| EV/Revenue | 10.99 |
| EV/EBITDA | 34.01 |
| Quarterly Earnings Growth (YoY) | 114.00% |
| Quarterly Revenue Growth (YoY) | 62.60% |
| Shares Outstanding | $62.19M |
| Float | $1.55B |
| % Insiders | 0.00% |
| % Institutions | 47.52% |
Historical Volatility
HV 10-Day
48.52%
HV 20-Day
39.95%
HV 30-Day
37.98%
HV 60-Day
33.28%
HV Rank
85.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($1028.58 target)
6
Strong Buy15
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026